Michael Lehmicke, Senior Director of Science & Industry Affairs, Alliance for Regenerative Medicine, Washington, D.C., describes the influence of ARM in the cell and gene therapy (GCT) industry and future plans for ARM within the sector. The A-Gene and A-Cell projects have been providing guidance to companies and academic institutions. Collaboration with the FDA and EMA, as well with the network of manufacturers and industry experts have additionally proven useful to address Chemistry, Manufacturing and Controls (CMC) issues. This interview took place at Advanced Therapies Week 2022.
Michael Lehmicke is the Senior Director of Science & Industry Affairs at Alliance for Regenerative Medicine.